EVOMMUNE SHARES DOWN 28% AFTER THE BELL; ANNOUNCES TOP-LINE RESULTS FROM EVO756 PHASE 2B TRIAL IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

Reuters · 23h ago

Please log in to view news